Bruno Pougault on the Limitations of DOACs in High-Risk Conditions
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
”DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”
Read the full article here.
Article: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
Authors: Antoine Bejjani, Candrika D. Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H. Talasaz, John Fanikos, Jean M. Connors, Deborah M. Siegal, Geoffrey D. Barnes, Karlyn A. Martin, Dominick J. Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S. V. Elkind, Christian T. Ruff, Samuel Z. Goldhaber, Harlan M. Krumholz, Roxana Mehran, Mary Cushman, John W. Eikelboom, Gregory Y. H. Lip, Jeffrey I. Weitz, Renato D. Lopes, Behnood Bikdeli
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies